An engineered L. reuteri secreting interleukin -22 was developed based on the probiotic L. reuteri ATCC PTA 6475 and could ameliorate non-alcoholic fatty liver disease [80]. Here, IL22 is linked to metabolic dysfunction-associated steatotic liver disease.